190 related articles for article (PubMed ID: 26052534)
1. Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera.
Watanabe N; Yano K; Tsuyuki K; Okano T; Yamato M
Mol Ther Methods Clin Dev; 2015; 2():14066. PubMed ID: 26052534
[TBL] [Abstract][Full Text] [Related]
2. Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021.
Naumann-Winter F; Wolter F; Hermes U; Malikova E; Lilienthal N; Meier T; Kalland ME; Magrelli A
Front Pharmacol; 2022; 13():920336. PubMed ID: 36034814
[No Abstract] [Full Text] [Related]
3. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
[TBL] [Abstract][Full Text] [Related]
4. [The use of nanotechnology in medicinal products in the light of European Union law].
Jurewicz M
Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European Union.
Narayanan G; Cossu G; Galli MC; Flory E; Ovelgonne H; Salmikangas P; Schneider CK; Trouvin JH
Hum Gene Ther Clin Dev; 2014 Mar; 25(1):1-6. PubMed ID: 24649836
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).
Salmon F; Grosios K; Petry H
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):53-65. PubMed ID: 24308784
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis.
Gaudet D; Stroes ES; Méthot J; Brisson D; Tremblay K; Bernelot Moens SJ; Iotti G; Rastelletti I; Ardigo D; Corzo D; Meyer C; Andersen M; Ruszniewski P; Deakin M; Bruno MJ
Hum Gene Ther; 2016 Nov; 27(11):916-925. PubMed ID: 27412455
[TBL] [Abstract][Full Text] [Related]
8. The European Medicines Agency facilitates access to medicines in low- and middle-income countries.
Cavaller Bellaubi M; Harvey Allchurch M; Lagalice C; Saint-Raymond A
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):321-325. PubMed ID: 32053756
[No Abstract] [Full Text] [Related]
9. Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan.
Halioua-Haubold CL; Peyer JG; Smith JA; Arshad Z; Scholz M; Brindley DA; MacLaren RE
Yale J Biol Med; 2017 Dec; 90(4):683-693. PubMed ID: 29259533
[TBL] [Abstract][Full Text] [Related]
10. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
11. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
Dejas-Eckertz P; Schäffner G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
[TBL] [Abstract][Full Text] [Related]
12. Regulatory structures for gene therapy medicinal products in the European Union.
Klug B; Celis P; Carr M; Reinhardt J
Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
[TBL] [Abstract][Full Text] [Related]
13. Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside.
Ferreira V; Petry H; Salmon F
Front Immunol; 2014; 5():82. PubMed ID: 24624131
[TBL] [Abstract][Full Text] [Related]
14. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
15. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
16. [Europe and medicines: role of the EMEA].
Sauer F
Ann Pharm Fr; 2000 Jul; 58(4):278-85. PubMed ID: 10915977
[TBL] [Abstract][Full Text] [Related]
17. A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020.
Teixeira MM; Borges FC; Ferreira PS; Rocha J; Sepodes B; Torre C
Front Med (Lausanne); 2022; 9():968272. PubMed ID: 36035431
[TBL] [Abstract][Full Text] [Related]
18. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
19. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
[TBL] [Abstract][Full Text] [Related]
20. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
Ferrario A
Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
